Delivery Order SPE2DB20D2014-SPE2DB25FC94M
- Not listed
- The Defense Logistics Agency awarded a $1,298.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a non-set-aside contract, indicating open competition. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. The...
- The Defense Logistics Agency awarded a $19,343.26 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens. This competitively awarded, firm fixed-price contract is classified as a non-set-aside procurement and requires completion by July 25, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a $16,297.57 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 14, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's demonstrated...
- The Defense Logistics Agency awarded a $13,067.60 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens under a firm fixed price contract. The order is scheduled for completion by August 8, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation and represents a relatively small-value transaction...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,785.59 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pens on July 18, 2025, with completion scheduled for July 21, 2025. This competitively awarded, firm fixed-price delivery order represents part of AmerisourceBergen's broader pharmaceutical supply operations supporting federal medical procurement needs. The company, headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a $1,871.51 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on July 28, 2025, with completion targeted for July 29, 2025. This non-competitive delivery order is issued against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $10,128.30 to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pens. This is a firm fixed-price delivery order with a completion date of August 21, 2025, issued under a competitive procurement with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with...
- The Defense Logistics Agency awarded a $17,564.19 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a small-value transaction within the company's...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens. The contract, valued at $31,254.75 with a firm fixed price structure, was awarded on August 19, 2025, with an ultimate completion date of August 20, 2025. This delivery order represents a non-competitive, non-set-aside award executed under an existing contract...
- The Defense Logistics Agency awarded a $2,889.13 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pens on July 30, 2025, with completion targeted for July 31, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitively awarded delivery order for pharmaceutical supply to support federal healthcare needs. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC94MDelivery Order
The Defense Logistics Agency awarded a $32,717.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pens on September 8, 2025, with an ultimate completion date of September 9, 2025. This non-competitive delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million and extending through December 2026. The contract was fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a routine pharmaceutical procurement within AmerisourceBergen's comprehensive global pharmaceutical support vehicle, which enables the company to supply a broad range of medications and medical supplies to support military healthcare programs and federal medical procurement needs. As a major pharmaceutical distributor, AmerisourceBergen serves critical federal customers including the Defense Health Agency and U.S. Coast Guard through its established IDC arrangements with the DLA, demonstrating the company's capability to meet specialized pharmaceutical requirements for defense and veteran healthcare systems on a competitive basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $32.7k | 9/8/25 |